April 6 (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday withdrew its approval for Covis Pharma's preterm birth prevention drug, Makena, saying that the drug was not effective in ...

When a long-awaited FDA hearing over Covis Pharma’s recurrent preterm birth drug Makena kicked off Monday, the agency paraded out a half dozen of its experts to convince the panel it should recommend ...

Earlier this month, Switzerland-based Covis Pharma announced it would voluntarily pull Makena, an unproven drug intended to prevent premature births, from the U.S. market. The March 7 announcement ...

The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the U.S., after regulators signaled plans to follow through on a long-delayed effort ...

More than a decade after Makena's FDA approval to prevent recurrent preterm birth and two years after the FDA recommended the drug be pulled from the market, Covis Pharma has locked down a hearing ...

Please provide your email address to receive an email when new articles are posted on . Covis Pharma will voluntarily withdraw its preterm birth prevention drug Makena from the market. An FDA advisory ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration assertion comes over two years after they declared the drug Makena ineffective, which Covis ...

The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the U.S., after regulators signaled plans to follow through on a long-delayed effort ...

A pharmaceutical company selling the only drug approved to prevent preterm birth said Tuesday that it would withdraw the medicine from the market. Covis Pharma said it told the Food and Drug ...

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, has entered into a definitive asset ...